We applaud the thoughtful letter from Vialettes and Valéro ([@B1]) bringing attention to endoplasmic reticulum (ER) stress as a potential mechanism influencing the decline in β-cell function observed in individuals with type 1 diabetes. We agree that it is a plausible mechanism underlying the preservation of C-peptide seen with aggressive correction of metabolic dysregulation and look forward to the results of the DirectNet/Type 1 Diabetes TrialNet study this year testing the effects of state-of-the-art glycemic control including closed-loop therapy at time of diagnosis on C-peptide. Intriguingly, the current studies referred to by Vialettes and Valéro in the NOD mouse suggest that ER stress antedate the onset of hyperglycemia ([@B2]). Previous work in animal models suggested that putting the β-cell to rest with diaxozide or insulin would prevent disease progression ([@B3]--[@B5]). In humans, although the Diabetes Prevention Trial--Type 1 parenteral insulin study was unable to demonstrate an effect of insulin therapy to prevent type 1 diabetes ([@B6]), the β-cell rest hypothesis in that trial was not fully tested as β-cell rest outside the yearly 4-day period of intravenous insulin infusion did not occur. Whether β-cell rest would be sufficient to repair or reduce ER stress in humans is unknown. The current challenge is to identify and evaluate biomarkers of β-cell ER stress in peripheral blood of individuals at risk for or with type 1 diabetes. In this way the role of β-cell ER stress in humans can be studied and appropriate intervention trials designed.
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